Insider Selling: Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Sells 3,012 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 3,012 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $8.19, for a total value of $24,668.28. Following the sale, the chief executive officer now owns 28,537 shares of the company’s stock, valued at approximately $233,718.03. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Precision BioSciences Stock Down 0.7 %

Shares of DTIL opened at $8.40 on Thursday. The firm has a market cap of $60.77 million, a price-to-earnings ratio of 140.00 and a beta of 1.71. The company’s fifty day moving average is $9.31 and its 200-day moving average is $10.05. Precision BioSciences, Inc. has a 12 month low of $7.97 and a 12 month high of $19.43.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a research report on Thursday, August 22nd.

Institutional Investors Weigh In On Precision BioSciences

An institutional investor recently bought a new position in Precision BioSciences stock. Janus Henderson Group PLC purchased a new position in Precision BioSciences, Inc. (NASDAQ:DTIL) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned about 8.29% of Precision BioSciences at the end of the most recent reporting period. 37.99% of the stock is owned by institutional investors and hedge funds.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.